CT引导HDR近距离放疗治疗HCC的病理结果及LI-RADS TRA评估
本研究回顾性分析19例肝细胞癌患者29个病灶在接受CT引导高剂量率间质近距离放疗后行肝移植的病理结果,并评估LI-RADS放疗反应算法v2024的诊断效能。结果显示65.5%病灶达完全病理坏死,移植前MRI无病灶判为LR-TR viable,所有判为LR-TR nonviable的病灶均证实完全病理坏死。
要点
- CT引导HDR-BT后移植间隔>136天者完全坏死率显著更高(86.7% vs 42.9%,p=0.026)。
- LI-RADS Radiation TRA v2024判为LR-TR nonviable的病灶均达完全病理坏死。
- 残留存活区可见TUNEL染色证实的凋亡活性,提示放疗后存在持续细胞死亡。
核心结论
- HDR-BT在移植肝中实现较高完全病理坏死率,LI-RADS Radiation TRA v2024在评估治疗反应方面表现良好。
研究设计与样本
- 单中心回顾性研究,纳入19例HCC患者共29个病灶,均于肝移植前接受CT引导HDR-BT。
- 以移植肝病理为参考标准,由两名阅片者用移植前MR图像评估LI-RADS治疗反应分类。
- 连续变量以中位数作为截断值,分析操作参数与完全病理坏死的关联。
关键影像表现/征象
- 移植前MRI按LI-RADS Radiation TRA v2024评估,无病灶被归类为LR-TR viable。
- 残留存活区域经TUNEL染色确认存在凋亡活动,提示放疗后仍有持续肿瘤细胞死亡。
诊断标准与关键数值
- 29个病灶中19个(65.5%)在病理上达到完全坏死,其余10个均显示超过50%肿瘤坏死。
- HDR-BT至移植间隔>136天组完全坏死率86.7%,≤136天组42.9%,p=0.026。
- 所有判为LR-TR nonviable的病灶在病理上均证实完全坏死。
临床应用与阅片要点
- LI-RADS Radiation TRA v2024的LR-TR nonviable分类在预测完全病理坏死方面可靠性较高,可用于移植前无创评估。
- 移植前MRI未见LR-TR viable病灶,提示HDR-BT后残留强化表现少见。
- 解读放疗后HCC影像时,应注意放疗与移植间隔较长者可能获得更高完全坏死率。
局限性
- 单中心回顾性设计,样本量较小(19例患者、29个病灶)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the histopathological outcomes after CT-guided high-dose-rate interstitial brachytherapy (HDR-BT) in hepatocellular carcinoma (HCC) patients and to assess the performance of the Liver Imaging Reporting and Data System (LI-RADS) Radiation treatment response algorithm (TRA).
MATERIALS AND METHODS: This retrospective analysis evaluated 19 patients with 29 HCC lesions who underwent HDR-BT before liver transplantation in a single center. Lesions were evaluated for the degree of tumor necrosis on explant histopathology. The association between procedural characteristics and complete pathological necrosis on histopathology was evaluated. The medians of continuous variables were used as cutoff values. The diagnostic value of LI-RADS treatment response (LR-TR) categories was evaluated by two readers using pre-transplantation MR images.
RESULTS: Histopathological evaluation revealed complete pathological necrosis in 19 lesions (65.5%). The remaining 10 lesions all demonstrated more than 50% tumor necrosis and showed clear evidence of apoptotic activity within the residual viable areas, as confirmed by TUNEL staining. Lesions of patients with a longer interval (> 136 days) between HDR-BT and transplantation showed significantly higher rates of complete necrosis (86.7% vs. 42.9%, p = 0.026), suggesting ongoing radiation-induced cell death and potentially therapy-induced senescence beyond the time of histological sampling. No lesion was categorized as LR-TR viable on pre-transplant MRI according to LI-RADS Radiation TRA v2024. All lesions classified as LR-TR nonviable demonstrated complete pathological necrosis on histology.
CONCLUSION: HDR-BT is associated with high rates of complete pathological necrosis in explanted livers, while LI-RADS Radiation TRA demonstrates promising performance in assessing treatment response.
KEY POINTS: Question Histopathological outcomes after CT-guided high-dose-rate brachytherapy (HDR-BT) and the predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm in hepatocellular carcinoma remain insufficiently defined. Findings CT-guided HDR-BT achieves high rates of complete pathological necrosis in HCC lesions, with treatment response accurately predicted by the LI-RADS Radiation TRA. Clinical relevance HDR-BT seems to be an effective bridging therapy for HCC, providing local control and high necrosis rates. LI-RADS Radiation TRA enables accurate, standardized imaging assessment to guide management and optimize timing toward transplantation.
引用
- Öcal, Öcal, Corradini, et al. Histopathological outcomes of CT-guided high-dose-rate interstitial brachytherapy for HCC and predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm v2024. Eur Radiol. 2026. PMID: 42268301. doi:10.1007/s00330-026-12674-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。